يعرض 1 - 5 نتائج من 5 نتيجة بحث عن '"Taal, Walter"', وقت الاستعلام: 1.25s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

    المؤلفون: Taal, Walter1, Oosterkamp, Hendrika M.2, Walenkamp, Annemiek M. E.3, Dubbink, Hendrikus J.4, Beerepoot, Laurens V.5, Hanse, Monique C. J.6, Buter, Jan7, Honkoop, Aafke H.8, Boerman, Dolf9, de Vos, Filip Y. F.10, Dinjens, Winand N. M.4, Enting, Roelien H.11, Taphoorn, Martin J. B.12, van den Berkmortel, Franchette W. P. J.13, Jansen, Rob L. H.14, Brandsma, Dieta15, Bromberg, Jacoline E. C.1, van Heuvel, Irene1, Vernhout, René M.16, van der Holt, Bronno16

    المصدر: Lancet Oncology. Aug2014, Vol. 15 Issue 9, p943-953. 11p.

    مصطلحات موضوعية: *BEVACIZUMAB, *GLIOBLASTOMA multiforme, *RANDOMIZED controlled trials, *CANCER chemotherapy, *HYPERTENSION, *CONTROL groups, *PATIENTS


    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Bevacizumab alone or in combination with chemotherapy in glioblastomas?-Authors' reply.

    المؤلفون: van den Bent, Martin J (AUTHOR), Taal, Walter (AUTHOR), BELOB co-investigators (CORPORATE AUTHOR)

    المصدر: Lancet Oncology. Oct2014, Vol. 15 Issue 11, pe473-4. 1p.


    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Bevacizumab alone or in combination with chemotherapy in glioblastomas?–Authors' reply.

    المؤلفون: van den Bent, Martin J1 m.vandenbent@erasmusmc.nl, Taal, Walter1

    المصدر: Lancet Oncology. Oct2014, Vol. 15 Issue 11, pe473-e474. 1p.

    مصطلحات موضوعية: *BEVACIZUMAB, *CANCER chemotherapy, *GLIOBLASTOMA multiforme treatment, *ONCOLOGY research, *ANTINEOPLASTIC agents


    أضف إلى المفضلة
  4. 4
    دورية أكاديمية
    Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

    المؤلفون: Brandsma, Dieta1,2, Stalpers, Lukas3, Taal, Walter1, Sminia, Peter4, van den Bent, Martin J1 m.vandenbent@erasmusmc.nl

    المصدر: Lancet Oncology. May2008, Vol. 9 Issue 5, p453-461. 9p.

    مصطلحات موضوعية: *ALKYLATING agents, *ASTROCYTOMAS, *BRAIN cancer, *GLIOBLASTOMA multiforme, *DRUG therapy


    أضف إلى المفضلة
  5. 5
    دورية أكاديمية
    Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.

    المؤلفون: van den Bent, Martin J1 (AUTHOR) m.vandenbent@erasmusmc.nl, Tesileanu, C Mircea S1 (AUTHOR), Wick, Wolfgang2 (AUTHOR), Sanson, Marc3,4 (AUTHOR), Brandes, Alba Ariela5 (AUTHOR), Clement, Paul M6 (AUTHOR), Erridge, Sarah7 (AUTHOR), Vogelbaum, Michael A8 (AUTHOR), Nowak, Anna K9,10,11 (AUTHOR), Baurain, Jean Français12 (AUTHOR), Mason, Warren P13 (AUTHOR), Wheeler, Helen14 (AUTHOR), Chinot, Olivier L15 (AUTHOR), Gill, Sanjeev16 (AUTHOR), Griffin, Matthew17 (AUTHOR), Rogers, Leland18 (AUTHOR), Taal, Walter1 (AUTHOR), Rudà, Roberta19 (AUTHOR), Weller, Michael20 (AUTHOR), McBain, Catherine21 (AUTHOR)

    المصدر: Lancet Oncology. Jun2021, Vol. 22 Issue 6, p813-823. 11p.

    مصطلحات موضوعية: *TEMOZOLOMIDE, *OVERALL survival, *BRAIN tumors, *GLIOMAS, *INTENSITY modulated radiotherapy, *ADJUVANT chemotherapy, *CHROMOSOMES, *GENETIC mutation, *DACARBAZINE, *RANDOMIZED controlled trials, *OXIDOREDUCTASES, *RADIOTHERAPY, *COMBINED modality therapy, *STATISTICAL sampling

    مصطلحات جغرافية: EUROPE, NORTH America, AUSTRALIA

    الشركة/الكيان: MERCK KGaA


    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث